Nerve regeneration tech targets Alzheimer’s and Nasdaq

Latest articles

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

VIDEO: The Science of Ovarian Longevity

Instead of papering over the cracks of declining fertility and the effects of menopause, what else can we do to help the longevity of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

Click the globe for translations.

NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021.

With a unique nerve regeneration technology, Canadian biotech NervGen is preparing to commence with Phase 1 clinical trials of its lead compound, which the company is developing for the treatment of spinal cord injury and neurodegenerative diseases, including Alzheimer’s and multiple sclerosis. The publicly traded company is currently listed on the Toronto Stock Exchange, and is also aiming to “uplist” onto the US NASDAQ exchange in the near future.

Longevity.Technology: As we age, our brain’s neuroplasticity, or its ability to adapt and change in response to new experiences, is reduced. Part of this is due to a reduced ability to make new connections between neurons, and NervGen is focused on inhibiting the part of our biology that causes this. We caught up recently with the company’s CEO Paul Brennan to learn more.

The origins of NervGen’s technology stem from the work of Dr Jerry Silver, Professor of Neurosciences at Case Western Reserve University. Around 30 years ago, Silver discovered that a glycoprotein called chondroitin sulfate proteoglycan (CSPG) was a major inhibitor of our body’s natural ability to regrow and regenerate the central nervous system.

Dr Silver
Dr Jerry Silver, Professor of Neurosciences at Case Western Reserve University.

“He was able to identify that it was the CSPGs that were preventing the repair you would hope to see at the site of an injury in the spinal cord,” says Brennan. “He then identified a receptor [protein tyrosine phosphatase sigma or PTPσ] that would detect the CSPGs, and then he was finally able to identify a molecule that would inhibit the receptor. So by inhibiting the inhibition, you allow repair or growth to occur.”

Potential in neurodegenerative disease

While the initial focus of Silver’s research was on spinal cord injury, it is also thought that modulating PTPσ has the potential to alter pathology of neurodegenerative diseases, including Alzheimer’s and multiple sclerosis, by promoting regeneration at areas of nerve damage and improving plasticity in intact areas of the brain.

NervGen came into being in 2018 after Dr Harold Punnett, a Vancouver-based dentist, came across Silver’s work while researching spinal cord injury science after his daughter-in-law became a paraplegic after a fall.

“He realised that Dr Silver was completely unaffiliated with any company at the time,” says Brennan. As it turns out, Punnett was also part of an investment group of high net worth individuals who would invest in technologies, take them out of universities and create companies.

“It took two years to negotiate with the tech transfer office to negotiate the licence. But they were able to do it and then funded NervGen with a $2 million round to start the company, followed by an IPO on the Toronto Stock Exchange in 2019.”

Nerve regeneration: from laboratory to drug

The company then set about proving that Silver’s work could be developed as a drug – all the pharmaceutical development work, manufacturing, toxicology studies and pharmacokinetics characterizations. This work has culminate in NervGen’s lead compound, NVG-291, which the company believes has “potential as a therapeutic for diseases that are related to nerve damage, either as a result of injury, neurodegenerative disease, or other causes.”

“We’re just moving from preclinical to Phase 1 – we’ve got the approval in the US to proceed,” says Brennan. “So we’re just going through ethics approval, and we’ll be dosing our first patients by mid year.”

With the initial Phase 1 trial in healthy volunteers expected to complete this year, NervGen hopes to initiate a Phase 1b Alzheimer’s trial and Phase 2 trials for multiple sclerosis and spinal cord injury next year.

“If this works, it will be the first product that can be used broadly across nerve damage,” says Brennan. “And it’ll be used as broadly as steroids are used now for inflammation – it will be that definitive and that much of a revolution in terms of a therapy.”

Aiming for the NASDAQ

In addition to all the clinical trials coming up, Brennan is also placing a “high priority” on getting the company uplisted to the NASDAQ stock exchange.

“There’s a huge disparity in valuations of companies that are on the NASDAQ versus companies that are not on the NASDAQ,” says Brennan. “So there’s definitely a benefit for us to get on to the NASDAQ, both in terms of valuation – and liquidity, which ultimately reaches through to valuation as well. It’d be nice to do it by the end of the year, or certainly a short time after that.”

Images courtesy of NervGen
Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

$70m collaboration to redefine aging research

Astera Institute and Buck Institute announce $70 million collaboration to redefine the field of research on aging. The Buck Institute for Research on Aging and...

A new approach to reversing tissue aging

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale...

Rejuveron leads €15.7m series B in Rejuvenate Biomed

Investment in Rejuvenate Biomed set to accelerate clinical development of its sarcopenia treatment for healthy aging. Rejuveron Life Sciences, a Zürich-based biotechnology company developing therapies...

Ovarian aging – your questions answered

Ovarian longevity and the significance of ovarian aging is poorly understood – our video aims to change that. Join our Scientific Editor Daragh Campbell as...

Learning lessons from clinical trial failure

Metabesity 2021: Joan Mannick talks longevity scientific breakthroughs, healthspan endpoints, her new role at Life Biosciences, and what can be learned from resTORbio’s clinical...